Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

As it gets harder to offer compounded GLP-1s, many telehealth companies are pivoting to hormone replacement therapy.

ABC News' Dr. Tara Narula breaks down the FDA's decision to stop the making of compound versions of weight loss medications.

Increasing access to these effective evidence-based treatments would benefit our society as a whole, not just those impacted ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

By Brian Brown, president and partner at food marketing agency Ingredient  For those living on the West Coast of North ...

Eli Lilly has stockpiled nearly $550 million worth of its next obesity drug, orforglipron, despite it being at least a year ...

Could taking tiny fractions of the normal prescribed dose of a medication offer a brilliant way to benefit from the drug, ...

Mizuho healthcare equity strategist Jared Holz joins Julie Hyman and Josh Lipton on Market Domination to analyze the GLP-1 ...

"We will have to start notifying customers in the coming month and two that they will ... for a fraction of Novo's prices. Hims' GLP-1 drugs start at $199 a month, while Wegovy and Ozempic cost ...

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...